臨床試験市場：デザイン、フェーズ、適応症別-2025-2030年の世界予測

臨床試験市場は、2023年に383億米ドルと評価され、2024年には417億8,000万米ドルに達すると予測され、CAGR 9.16％で成長し、2030年には707億8,000万米ドルに達すると予測されています。

臨床試験市場は、ヒトを対象とした医薬品、機器、治療試験のあらゆる段階を網羅し、一般に販売される前に新しい治療法の有効性と安全性を保証する開発パイプラインの重要な構成要素として機能しています。臨床試験の必要性は、規制当局の承認に不可欠なデータを提供し、革新的な解決策で進化する疾患と闘う必要性から生じる。これらの調査は、製薬、バイオテクノロジー、医療機器業界に幅広く適用され、最終用途は病院、研究機関、医薬品開発業務受託機関（CRO）です。成長に大きな影響を与える要因としては、生物医学研究の進歩、慢性疾患の増加、試験デザインやデータ収集におけるAIや機械学習などの技術統合などが挙げられます。市場参入企業にとっての新たなビジネスチャンスは、遠隔医療やモバイルヘルス技術を活用して患者の募集と維持を改善する分散型臨床試験（DCT）に集中しています。しかし、市場の成長は、複雑な試験デザインを管理するための物流上の課題とともに、高いコスト、厳しい規制要件、倫理的な問題によって制約されています。技術革新と研究を活用するために、利害関係者は、参加者の関与を合理化するためのデジタルヘルスツールの統合や、中間結果に基づいてリアルタイムの修正を可能にする適応試験デザインの探求に重点を置くことができます。患者募集と実環境でのエビデンス収集のための革新的なプラットフォームは、試験の効率と成果を高めることができます。さらに、製薬企業、CRO、テクノロジープロバイダーがパートナーシップを構築することで、試験管理におけるリソースや専門知識の共有を促進することができます。競合情勢は、世界プレイヤーと地域プレイヤーで構成され、それぞれが独自の能力を活用して市場参入を拡大しています。このダイナミックな市場に関する洞察は、精密医療、ゲノム研究、特殊医薬品が勢いを増すにつれ、継続的な成長を示唆しています。規制状況を戦略的にナビゲートしながら、臨床試験の透明性と患者中心主義を強化することで、臨床試験セクターにおける将来の成長への強固な道筋を示すことができます。

市場力学：急速に進化する臨床試験市場の主要市場インサイトを公開

臨床試験市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 疾病の有病率の上昇とCROの統合による臨床試験の改善
  • 製薬・バイオ医薬品業界の研究開発費の増加
  • ジェネリック医薬品および生物製剤の開発・商業化への注力の高まり
• 市場抑制要因
  • 薬剤開発コストの増加、熟練した臨床研究専門家の不足
• 市場機会
  • 医薬品開発への注力の高まりと患者中心へのシフト臨床試験
  • 臨床試験の世界化の進展と規制の調和
• 市場の課題
  • 患者登録に関する厳しい規制と国境を越えた物流の課題

ポーターの5つの力：臨床試験市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：臨床試験市場における外部からの影響の把握

外部マクロ環境要因は、臨床試験市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析臨床試験市場における競合情勢の把握

臨床試験市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス臨床試験市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、臨床試験市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨臨床試験市場における成功への道筋を描く

臨床試験市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • CRO統合による疾病罹患率の上昇と臨床試験の改善
    • 医薬品・バイオ医薬品業界の研究開発費の増加
    • ジェネリック医薬品と生物製剤の開発と商業化への重点化
  • 抑制要因
    • 医薬品開発コストの増加と熟練した臨床調査専門家の不足
  • 機会
    • 医薬品開発への重点強化と患者中心への移行臨床試験
    • 臨床試験の世界化と規制の調和の進展
  • 課題
    • 患者登録に関する厳しい規制と国境を越えた物流の課題
• 市場セグメンテーション分析
  • デザイン：治療の有効性、リスク、安全性の評価を最適化するための介入および観察臨床試験デザインの重要性
  • 段階：薬物代謝のモニタリングと初期データの収集のための臨床試験の段階的実施
  • 適応症：慢性疾患、心血管疾患、その他の有害な疾患に対する適切な治療法や投薬を示唆するいくつかの適応症
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 臨床試験市場：設計別

• 介入研究
  • アダプティブ臨床試験
  • 非ランダム化比較試験
  • ランダム化比較試験
• 観察研究
  • 症例対照研究
  • コホート研究
  • 横断研究
  • 生態学研究

第7章 臨床試験市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII
• フェーズIV

第8章 臨床試験市場適応症別

• 自己免疫/炎症
• 心臓血管
• 中枢神経系の状態
• 糖尿病
• 感染症
• 肥満
• 腫瘍学
• 疼痛管理

第9章 南北アメリカの臨床試験市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の臨床試験市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの臨床試験市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • コールバーグがワールドワイドの過半数株式を取得臨床試験
  • アルカンザとレベレスが提携し、過小評価されているコミュニティにおける包括的な臨床調査を拡大
  • ブリストル・マイヤーズスクイブとヤンセンの共同研究が、経口因子XIa阻害剤ミルベキアンを評価する重要な第3相リブレキシア臨床試験プログラムを開始
• 戦略分析と提言

企業一覧

• ProPharma Group Holdings, LLC
• Charles River Laboratories International, Inc.
• Accell Clinical Research, LLC
• Congenix LLP
• Parexel International Corporation
• Qiagen NV
• SGS S.A.
• Bristol-Myers Squibb Company
• Bio-Rad Laboratories, Inc.
• SIRO Clinpharm Private Limited
• Novo Nordisk A/S
• Pfizer Inc.
• Clinipace
• Atlant Clinical Ltd.
• Quipment SAS
• Labcorp
• IQVIA Holdings, Inc.
• Becton, Dickinson and Company
• Merck KGaA
• Eli Lilly and Company
• Syneos Health, Inc.
• Wuxi AppTec Inc.
• Thermo Fisher Scientific Inc.
• Icon PLC
• Sartorius AG
• Illumina, Inc

LIST OF FIGURES

• FIGURE 1. CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CLINICAL TRIALS MARKET DYNAMICS
• TABLE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 51. CANADA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 52. CANADA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 53. CANADA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 77. CHINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 78. CHINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 79. CHINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 80. CHINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 82. INDIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 83. INDIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 84. INDIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 85. INDIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 168. ITALY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 169. ITALY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 170. ITALY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 171. ITALY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 188. POLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 189. POLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 190. POLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 191. POLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 193. QATAR CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 194. QATAR CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 195. QATAR CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 196. QATAR CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 242. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 243. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

The Clinical Trials Market was valued at USD 38.30 billion in 2023, expected to reach USD 41.78 billion in 2024, and is projected to grow at a CAGR of 9.16%, to USD 70.78 billion by 2030.

The clinical trials market encompasses all phases of drug, device, and treatment testing on human subjects, serving as a critical component in the development pipeline that assures the efficacy and safety of new therapies before they reach the public. The necessity of clinical trials arises from the need to combat evolving diseases with innovative solutions, providing vital data for regulatory approvals. These trials are broadly applicable across pharmaceutical, biotechnology, and medical device industries, with end-use in hospitals, research institutes, and contract research organizations (CROs). Significant growth influencers include advancements in biomedical research, increased prevalence of chronic diseases, and technological integration such as AI and machine learning in trial design and data collection. Emerging opportunities for market participants center around decentralized clinical trials (DCTs), which utilize telehealth and mobile health technologies to improve patient recruitment and retainment. However, market growth is constrained by high costs, stringent regulatory requirements, and ethical issues, along with logistical challenges in managing complex trial designs. To capitalize on innovation and research, stakeholders could focus on integrating digital health tools to streamline participant engagement or exploring adaptive trial designs that permit real-time modifications based on interim results. Innovative platforms for patient recruitment and real-world evidence collection can enhance trial efficiency and outcomes. Furthermore, developing partnerships between pharmaceutical companies, CROs, and technology providers can facilitate the sharing of resources and expertise in trial management. The competitive landscape comprises both global and regional players, each leveraging unique capabilities to expand market reach. Insight into this dynamic market suggests continual growth as precision medicine, genomic studies, and specialty pharmaceuticals gain momentum. Strategically navigating regulatory landscapes while enhancing trial transparency and patient centricity can offer a robust pathway for future growth in the clinical trials sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Trials Market

The Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of diseases and improved clinical trials due to CRO consolidation
  • Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
  • Increased focus on the development and commercialization of generics and biologics
• Market Restraints
  • Increased cost of drug development and lack of skilled clinical research professional
• Market Opportunities
  • Increased focus on drug development and shift towards patient-centric clinical trials
  • Growing globalization of clinical trials and harmonization of regulations
• Market Challenges
  • Stringent regulations for patient enrollment and cross-border logistics challenges

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Trials Market

A detailed market share analysis in the Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Trials Market

A strategic analysis of the Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include ProPharma Group Holdings, LLC, Charles River Laboratories International, Inc., Accell Clinical Research, LLC, Congenix LLP, Parexel International Corporation, Qiagen NV, SGS S.A., Bristol-Myers Squibb Company, Bio-Rad Laboratories, Inc., SIRO Clinpharm Private Limited, Novo Nordisk A/S, Pfizer Inc., Clinipace, Atlant Clinical Ltd., Quipment SAS, Labcorp, IQVIA Holdings, Inc., Becton, Dickinson and Company, Merck KGaA, Eli Lilly and Company, Syneos Health, Inc., Wuxi AppTec Inc., Thermo Fisher Scientific Inc., Icon PLC, Sartorius AG, and Illumina, Inc.

Market Segmentation & Coverage

This research report categorizes the Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Design, market is studied across Interventional Study and Observational Study. The Interventional Study is further studied across Adaptive Clinical Trial, Non-randomized Control Trial, and Randomized Control Trial. The Observational Study is further studied across Case Control Study, Cohort Study, Cross Sectional Study, and Ecological Study.
• Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
• Based on Indication, market is studied across Autoimmune/Inflammation, Cardiovascular, CNS condition, Diabetes, Infectious Diseases, Obesity, Oncology, and Pain management.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of diseases and improved clinical trials due to CRO consolidation
    • 5.1.1.2. Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
    • 5.1.1.3. Increased focus on the development and commercialization of generics and biologics
  • 5.1.2. Restraints
    • 5.1.2.1. Increased cost of drug development and lack of skilled clinical research professional
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased focus on drug development and shift towards patient-centric clinical trials
    • 5.1.3.2. Growing globalization of clinical trials and harmonization of regulations
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations for patient enrollment and cross-border logistics challenges
• 5.2. Market Segmentation Analysis
  • 5.2.1. Design: Importance of interventional and observational clinical trial design to optimize assessment of treatment efficacy, risk, and safety
  • 5.2.2. Phase: clinical trial phases in for monitoring drug metabolism and gathering initial data
  • 5.2.3. Indication: Several indications suggesting suitable treatments and medications for chronic, cardiovascular, and other harmful diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Clinical Trials Market, by Design

• 6.1. Introduction
• 6.2. Interventional Study
  • 6.2.1. Adaptive Clinical Trial
  • 6.2.2. Non-randomized Control Trial
  • 6.2.3. Randomized Control Trial
• 6.3. Observational Study
  • 6.3.1. Case Control Study
  • 6.3.2. Cohort Study
  • 6.3.3. Cross Sectional Study
  • 6.3.4. Ecological Study

7. Clinical Trials Market, by Phase

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phase II
• 7.4. Phase III
• 7.5. Phase IV

8. Clinical Trials Market, by Indication

• 8.1. Introduction
• 8.2. Autoimmune/Inflammation
• 8.3. Cardiovascular
• 8.4. CNS condition
• 8.5. Diabetes
• 8.6. Infectious Diseases
• 8.7. Obesity
• 8.8. Oncology
• 8.9. Pain management

9. Americas Clinical Trials Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Clinical Trials Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Clinical Trials Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Kohlberg Acquires Majority Stake in Worldwide Clinical Trials
  • 12.3.2. Alcanza and Reveles Partner to Expand Inclusive Clinical Research in Underrepresented Communities
  • 12.3.3. The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ProPharma Group Holdings, LLC
• 2. Charles River Laboratories International, Inc.
• 3. Accell Clinical Research, LLC
• 4. Congenix LLP
• 5. Parexel International Corporation
• 6. Qiagen NV
• 7. SGS S.A.
• 8. Bristol-Myers Squibb Company
• 9. Bio-Rad Laboratories, Inc.
• 10. SIRO Clinpharm Private Limited
• 11. Novo Nordisk A/S
• 12. Pfizer Inc.
• 13. Clinipace
• 14. Atlant Clinical Ltd.
• 15. Quipment SAS
• 16. Labcorp
• 17. IQVIA Holdings, Inc.
• 18. Becton, Dickinson and Company
• 19. Merck KGaA
• 20. Eli Lilly and Company
• 21. Syneos Health, Inc.
• 22. Wuxi AppTec Inc.
• 23. Thermo Fisher Scientific Inc.
• 24. Icon PLC
• 25. Sartorius AG
• 26. Illumina, Inc